Baidu
map

Eur Ann Allergy Clin Immunol:过敏性结膜炎的严重程度和持续时间与过敏性鼻炎和哮喘的严重程度和持续时间有关吗?

2021-08-15 AlexYang MedSci原创

过敏性结膜炎(AC)是一种由免疫球蛋白(Ig)E超敏反应介导的结膜炎症反应。根据不同的地理区域和研究设计,AC在普通人群中的估计患病率在15-40%之间。

过敏性结膜炎(AC)是一种由免疫球蛋白(Ig)E超敏反应介导的结膜炎症反应。根据不同的地理区域和研究设计,AC在普通人群中的估计患病率在15-40%之间。

目前为止,人们对过敏性结膜炎(AC)与鼻炎和/或哮喘的关系了解甚少

近期,有研究人员将过敏性结膜炎共识文件(DECA)的标准应用于过敏性结膜炎患者群体的分类,以评估过敏性结膜炎的严重程度和持续时间与鼻炎和/或哮喘的关系

研究纳入了参加 "2015年过敏性疾病研究 "的有眼部症状的AC患者。研究人员按年龄组(小于或等于14岁和大于14岁)对人口统计学、根据DECA标准的分类、病因和合并症进行了评估。

研究共有2914名患者(年龄范围为1-90岁)纳入 了"Alergológica 2015 "研究中。其中,965名患者(33.1%)诊断为AC(77.5%大于14岁)。按照疾病的严重程度,分别有1.8%、46.4%和51.8%的AC分为重度、中度或轻度;按照疾病的持续时间,分别有51.6%和48.4%的患者分为间歇性或持续性。有4%的病人只患有AC。AC主要与鼻炎(88.4%)、哮喘(38.2%)、食物过敏(8.3%)和特应性皮炎(3.5%)有关。在过敏性呼吸道疾病中,鼻炎先于AC发生,而哮喘则后于AC发生。AC的严重程度和持续时间与鼻炎(两个年龄组的P<0.001)和哮喘(仅成人的P<0.001)的严重程度和持续时间有显著关系。

AC与鼻炎或哮喘之间的相关性

综上所述,使用新DECA标准对AC分类表明AC、鼻炎和哮喘的严重程度和持续时间之间存在直接关系。这些关系表明,AC应该认为是 "同一气道,同一疾病 "假说的一个组成部分。

原始出处:

M C Sánchez-Hernández , M T Dordal , A M Navarro et al. Severity and duration of allergic conjunctivitis: are they associated with severity and duration of allergic rhinitis and asthma? Eur Ann Allergy Clin Immunol. Jul 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645530, encodeId=c7661645530b1, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Sun Apr 24 02:43:04 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677506, encodeId=c25116e750652, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Feb 04 22:43:04 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047440, encodeId=8983204e44056, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 05 22:43:04 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329541, encodeId=ae791329541ad, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503686, encodeId=f1ba1503686d7, content=<a href='/topic/show?id=4f215634296' target=_blank style='color:#2F92EE;'>#持续时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56342, encryptionId=4f215634296, topicName=持续时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e29684821, createdName=zhwj, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645530, encodeId=c7661645530b1, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Sun Apr 24 02:43:04 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677506, encodeId=c25116e750652, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Feb 04 22:43:04 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047440, encodeId=8983204e44056, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 05 22:43:04 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329541, encodeId=ae791329541ad, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503686, encodeId=f1ba1503686d7, content=<a href='/topic/show?id=4f215634296' target=_blank style='color:#2F92EE;'>#持续时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56342, encryptionId=4f215634296, topicName=持续时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e29684821, createdName=zhwj, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645530, encodeId=c7661645530b1, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Sun Apr 24 02:43:04 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677506, encodeId=c25116e750652, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Feb 04 22:43:04 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047440, encodeId=8983204e44056, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 05 22:43:04 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329541, encodeId=ae791329541ad, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503686, encodeId=f1ba1503686d7, content=<a href='/topic/show?id=4f215634296' target=_blank style='color:#2F92EE;'>#持续时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56342, encryptionId=4f215634296, topicName=持续时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e29684821, createdName=zhwj, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645530, encodeId=c7661645530b1, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Sun Apr 24 02:43:04 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677506, encodeId=c25116e750652, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Feb 04 22:43:04 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047440, encodeId=8983204e44056, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 05 22:43:04 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329541, encodeId=ae791329541ad, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503686, encodeId=f1ba1503686d7, content=<a href='/topic/show?id=4f215634296' target=_blank style='color:#2F92EE;'>#持续时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56342, encryptionId=4f215634296, topicName=持续时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e29684821, createdName=zhwj, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-17 仁医06
  5. [GetPortalCommentsPageByObjectIdResponse(id=1645530, encodeId=c7661645530b1, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Sun Apr 24 02:43:04 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677506, encodeId=c25116e750652, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Feb 04 22:43:04 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047440, encodeId=8983204e44056, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 05 22:43:04 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329541, encodeId=ae791329541ad, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503686, encodeId=f1ba1503686d7, content=<a href='/topic/show?id=4f215634296' target=_blank style='color:#2F92EE;'>#持续时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56342, encryptionId=4f215634296, topicName=持续时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e29684821, createdName=zhwj, createdTime=Tue Aug 17 09:43:04 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-17 zhwj

相关资讯

Clin Exp Allergy:特应性皮炎合并哮喘的成人全因死亡增加

AD、哮喘或同时患有这两种疾病的成人死亡风险增加,与仅有哮喘相比,AD合并哮喘会增加患者死亡风险。

梅斯呼吸疾病进展(第007期)

往期参见:梅斯呼吸疾病进展(第006期)

PLoS One:过敏性鼻炎稳定以及吸烟减少情况下年轻成年人的哮喘却在增加

在20世纪下半叶,哮喘和过敏性鼻炎(AR)的患病率在世界大部分地区都有增加,包括瑞典。然而,后来的研究对患病率的趋势呈现了不一致的结果。一些研究报告表明,以前哮喘的上升趋势已经达到了稳定,特别是在儿童

Lancet Respirat Med:Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响

Tezepelumab治疗可显著减少哮喘患者气道粘膜下的嗜酸性粒细胞

JAMA:3D vs 2D方案用于持续性中重度哮喘的治疗

对于持续性中重度哮喘患者,吸入皮质类固醇、长效β2激动剂以及长效M受体拮抗剂的3D治疗方案显著降低患者严重哮喘发作风险,可适度改善哮喘控制,但在生活质量和死亡率无显著改善

Allergy Asthma Proc:哮喘和鼻炎控制对工作效率和活动障碍的交互影响

有症状的哮喘和鼻炎对患者的工作效率和活动有负面影响。然而,人们对哮喘和鼻炎控制对工作效率和活动障碍的潜在交互影响知之甚少。

Baidu
map
Baidu
map
Baidu
map